DehydraTECH-Vasodilatory Compound

DehydraTECH-Vasodilatory Compound is a preclinical small molecule drug candidate being developed by Cannabis Delivery Sciences, a subsidiary of Lexaria Bioscience, for the treatment of hypertension and other cardiovascular diseases. The formulation utilizes Lexaria's proprietary DehydraTECH drug delivery technology, which is designed to improve the bioavailability, speed of onset, and efficacy of lipophilic active pharmaceutical ingredients by enhancing their oral absorption. While the specific chemical identity and molecular target of the vasodilatory compound remain undisclosed, it is intended to induce vasodilation to reduce blood pressure. A pilot human clinical study has been completed, indicating that the program is progressing toward early-stage clinical validation.

Other names

Vasodilatory Compound (undisclosed)